LTR Pharma (ASX:LTP) reported 10 minute SPONTAN Tmax data with no serious safety events, strengthening its planned FDA pathway.
Life Sciences
Shares in Dimerix fell over 35% this morning and some may think the decline was irrational. After all, the announcement confirmed >90 per cent statistical power for its primary endpoint, reminded the market that its 2024 futility analysis showed the drug outperforming placebo, and reported no safety issues across seven IDMC reviews. On paper, that…
Percheron Therapeutics is not the kind of company that typically commands market attention at a A$6–7m valuation. Yet the more one looks at its trajectory over the past twelve months, the more it becomes clear that the market is missing something important. The company has moved from being a near‑dormant shell to a clinical‑stage immuno‑oncology…
The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their cash as they have earned on their investments. We felt that it was time to write a stand-alone article about this in light of the inflation crisis and how it could lead to investors seeking…
The imminent US Marijuana Rescheduling begs the question: Is it really different this time for ASX pot stocks? In one sense, perhaps it is, because it is undoubtedly the most significant policy signal in more than 50 years. But in the other, there's no promise it'll lead to anything, as recent history has shown.
What's Happening…
After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of that groundwork will likely pay off.
Dimerix has been advancing DMX-200/Qytovra for several years
DMX-200 is a targeted anti‑inflammatory therapy designed to block the CCR2 pathway…
Knowing how to read a balance sheet is a key skill investors need to know, because the balance sheet is the most underrated document in an annual report. Most new investors skip straight to earnings - perhaps not knowing how importance the balance sheet is or having an appreciate but not knowing how to read…
The ASX's 3 pathology stocks: Sonic Healthcare (ASX:SHL), Healius (ASX:HLS) and Australian Clinical Labs (ASX:ACL); have delivered a torrid experience for shareholders over the past two to three years.
Sonic, the global heavyweight, has fallen nearly 20% since early 2025 and recently traded at decade lows. Healius, long the sector’s problem child, has lost more than…
Add a new term to your vocabulary: The Iran Ceasefire Rally. The rally on the ASX yesterday, that saw our bourse rise over 2.5% in its best day in several months, occurred amidst a 2 week suspension of hostilities in Iran. And the ASX was not alone with Asian markets and North American futures rallying,…
ASX Biotech Investing has always been the market’s most difficult arena. Yes tech and resources are risky spaces too, but at least a gold explorer can gain just off the back of gold price momentum or activity from neighbouring peers.
With biotech it is all on the success of the individual company. The science is extraordinary…
